ReviewAmerican journal of respiratory cell and molecular biology2026
Mechanisms of upper airway muscle control in sleep reveal therapeutic targets for obstructive sleep apnea.
Review in American journal of respiratory cell and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).American journal of respiratory and critical care medicine · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Obstructive sleep apnea (OSA) is the most prevalent sleep-related breathing disorder and is associated with cardiovascular, metabolic, neurocognitive, and mortality risk. OSA arises from recurrent upper airway collapse during sleep, producing intermittent hypoxia and sleep fragmentation. While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake-sleep transition. Despite this central role, no approved pharmacologic therapies have targeted the neuromuscular mechanisms underlying airway collapse. This review summarizes the biological basis of upper airway neuromuscular dysfunction in OSA, integrating insights from preclinical models of hypoglossal motor control with clinical evidence supporting neuromodulatory treatment strategies. We focus on AD109, an investigational oral therapy combining a norepinephrine reuptake inhibitor (atomoxetine) with an antimuscarinic agent (aroxybutynin), designed to counteract sleep-related withdrawal of excitatory noradrenergic drive and rapid eye movement (REM)-related muscarinic inhibition at the hypoglossal motor nucleus. Early phase clinical studies demonstrated rapid and substantial improvements in airway collapsibility and apnea-hypopnea index, providing proof of concept for this approach. Results from large phase 3 trials confirm that targeting neuromuscular dysfunction can produce reductions in airway obstruction and meaningful improvements in oxygenation, including hypoxic burden, a metric closely linked to OSA-related sequelae. Symptomatic patients also experienced improvements in fatigue, sleepiness, and snoring versus placebo. Together, these findings support neuromuscular dysfunction as a tractable therapeutic target in OSA and highlight the potential of pharmacologic strategies to address both the physiological consequences of intermittent hypoxia and patient-relevant outcomes across a broad and heterogeneous OSA population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.